Tech Company Financing Transactions
BiPar Sciences Funding Round
On 2/27/2007, BiPar Sciences raised $35 million in Series B funding from Domain Associates, Asset Management Ventures and Canaan Partners.
Transaction Overview
Company Name
Announced On
2/27/2007
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
Proceeds Purpose
BiPar is developing multiple compounds designed to inhibit PARP 1 (poly-ADP-ribose polymerase), an enzyme that is crucial to cell repair and upregulated in certain tumors. The round fully funds the Company's robust Phase 2 program for its lead drug candidate, BSI-201, and accelerates development of two additional drug candidates from BiPar's pipeline.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 550
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
BiPar Sciences Inc. is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hoyoung Huh
Chief Financial Officer
John Schembri
Vice President
Barry Sherman
Vice President
Charles Bradley
VP - Marketing
Sunil Patel
VP - Regulatory Affairs
Deborah Thomas
Browse more venture capital transactions:
Prev: 2/27/2007: Terascala venture capital transaction
Next: 2/27/2007: Advanced Biohealing venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs